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Neuropathic pain can be caused by a variety of nerve lesions and it is 
unsettled whether it should be categorised into distinct clinical subtypes 
depending on aetiology or type of nerve lesion or individualised as a specific 
group, based on common symptomatology across aetiologies. 
In this study, we used a multivariate statistical method (multiple 
correspondence analyses) to investigate associations between neuropathic 
positive symptoms (assessed with a specific questionnaire, the Neuropathic 
Pain Symptom Inventory [NPSI]) and aetiologies, types of nerve lesion and pain 
localisations. We also examined the internal structure of the NPSI and its 
relevance to evaluation of symptoms of evoked pains by exploring their 
relationships with clinician-based quantified measures of allodynia and 
hyperalgesia.  
This study included 482 consecutive patients (53% men; mean age: 58 ± 
15 years) with pain associated with peripheral or central lesions. Factor analysis 
showed that neuropathic symptoms of the NPSI can be categorised into five 
dimensions. Spearman correlation coefficients indicated that self-reported pain 
evoked by brush, pressure and cold stimuli strongly correlated to 
allodynia/hyperalgesia to brush, von Frey hairs and cold stimuli (p < 0.0001, n = 
90). Multiple correspondence analyses indicated few associations between 
symptoms (or dimensions) and aetiologies, types of lesions, or pain 
localisations. Exceptions included idiopathic trigeminal neuralgia and 
postherpetic neuralgia.  
We found that there are more similarities than differences in the 
neuropathic positive symptoms associated with a large variety of peripheral and 
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central lesions, providing rationale for subgrouping aetiologically diverse 
neuropathic patients into a specific mulltidimensional category for therapeutic 
management.  
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An aetiologically highly heterogeneous group of patients experience 
neuropathic pain (NP) due to disease or a lesion of the nervous system. NP has 
many causes, but is characterised by the combination of a relatively small 
number of core positive symptoms (particularly burning pain, electric shocks, 
dysaesthesia and allodynia to brush) and negative signs (particularly sensory 
deficits) distinguishing it from other types of chronic pain (4, 6). We have recently 
shown that positive symptoms pertained to distinct dimensions (i.e. superficial 
pain, deep pain, paroxysmal pain, evoked pain) (8). However, it is unclear 
whether the multidimensional nature of NP is related to the aetiology or location 
of the neurological lesion. In other words, it has not been determined whether the 
various aetiologies are associated with specific or preferential symptom 
combinations or, in contrast, whether the clinical expression of NP is similar 
whatever the underlying cause.  
The symptoms probably reflect the pathophysiological mechanisms. Thus, 
such information may be useful for a mechanism-based approach for selecting 
therapy for neuropathic pain (3, 6, 7, 8, 19, 37). In particular, identification of sub-
syndromes corresponding to various combinations of symptoms (related or not to 
the aetiology) may contribute to reformation of current therapeutic strategies (7, 
8, 19). The traditional aetiology-based categorisation of neuropathic pain still 
prevails for clinical, experimental (20, 21) and pharmacological studies (1, 11, 
14). Pharmacological studies have evaluated neuropathic pain as a global and 
uniform symptom. This empirical approach may be a main cause of therapeutic 
failure in these patients (3, 7, 37).  
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In our study, we used a multivariate statistical method–multiple 
correspondence analyses (16, 17) to investigate the associations between 
neuropathic positive symptoms (and dimensions) and aetiologies, types and 
locations of neurological lesions in a large consecutive sample of patients with 
neuropathic pain. Negative symptoms or signs (ie, sensory deficits) were not 
included in these analyses, since they are expected to be more directly 
associated with nerve lesions. We assessed symptoms and dimensions with the 
Neuropathic Pain Symptom Inventory (NPSI), a recently validated questionnaire 
specifically designed for such a purpose (8). We also confirmed the internal 
structure of the NPSI and determined its relevance to evaluation of symptoms of 
evoked pain by exploring their relationships with clinician-based quantified 
measures (i.e. quantitative sensory testing) of allodynia and hyperalgesia.  
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2- METHODS  
 2.1. Patients  
Consecutive patients were recruited from the Pain Centre of Ambroise 
Paré Hospital (Boulogne-Billancourt) and the Pain Centre of Pasteur Hospital 
(Nice) between November 2004 and November 2006. Patients had pain 
attributed to a primary lesion of the peripheral or central nervous system 
confirmed by appropriate clinical examination by an experienced neurologist 
and/or additional investigations when required (eg, EMG in most cases of 
peripheral nerve lesions, spinal cord or brain MRI in patients with lesions of the 
central nervous system or trigeminal neuralgia). Patients were included if they 
were > 18 years old; had experienced pain for at least three months with a mean 
pain intensity   30/100; had the ability to understand, write and read French; and 
were making their first visit to the pain clinic. Patients were excluded from the 
study if they had somatic pain that was more severe than the neuropathic pain, 
pain of unknown aetiology, a severe progressive disease (eg, cancer, AIDS), a 
severe psychiatric condition (psychosis, severe depression), chronic alcoholism 
or substance abuse or a nerve injury that was not clearly identified (e.g. complex 
regional pain syndrome [CRPS] type I, stomatodynia and atypical facial pain).  
 2.2. Study design and recording  
All patients underwent standard clinical neurological examination focused 
on sensory deficits and evoked pain. They were asked to rate the mean intensity 
of their pain during the last 24 hours on an 11-point (0-10) numerical scale on the 
neuropathic pain symptom inventory (NPSI) (8). This questionnaire includes ten 
symptoms most commonly described by neuropathic patients (burning, pressure, 
squeezing, electric shocks, stabbing; pain evoked by brushing, pressure, or cold; 
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tingling, pins and needles). On factor analysis, these symptoms were categorised 
into five distinct dimensions (eg, combination of symptoms), as previously 
reported (8): superficial burning pain, deep pain, paroxysmal pain, allodynia and 
paraesthesia/dysaesthesia. The score obtained for each dimension (from 0 to 10) 
corresponded to the mean score for individual symptoms, as reported previously 
(e.g. deep pain corresponded to the mean score for pressure and squeezing, 
paroxysmal pain corresponded to the mean score for electric shocks and 
stabbing).  
 2.3. Quantitative sensory testing  
 Ninety patients from the Ambroise Paré hospital (with the exception of 
patients with amputation pain and trigeminal neuralgia) were randomly selected 
for a quantitative sensory assessment of allodynia and hyperalgesia by a second 
experienced investigator – blinded to results of the questionnaire – using a 
method largely described elsewhere (2, 10). Measurements were systematically 
taken in the affected area (the area of maximal pain determined on the day of 
assessment) and in a normal non-painful area. This normal area was usually on 
the homologous contralateral side, except in ten patients with painful 
polyneuropathy. In these patients, the control area was the closest area with 
normal sensitivity (i.e. the thigh). Tactile allodynia (dynamic) was tested for by 
stroking the skin three times with a paintbrush and was considered to be present if 
this evoked a clear sensation of pain. The intensity of allodynia within the area of 
maximal pain was recorded according to a visual analogue scale (VAS). The 
mean of three consecutive VAS scores was determined. Calibrated von Frey hairs 
(0.057 to 140 g) were used to assess detection and pain thresholds for static 
(punctate) mechanical stimuli. Thermal detection and pain thresholds were 
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assessed with a Somedic thermotest (Somedic AB, Stockholm, Sweden) by the 
method of limits, with baseline temperatures adjusted to the patient's skin 
temperature (mean 30.9 ± 0.5 °C). A contact thermode of Peltier elements 
measuring 25 x 50 mm was applied to the skin. Thresholds were calculated as the 
mean of five successive determinations for detection and three determinations for 
pain and were expressed as absolute thresholds (degrees C) as the difference 
between thermode neutral temperature and threshold temperatures. Pain induced 
by suprathreshold mechanical and cold stimuli applied in a pseudo-random order 
was rated on a VAS. Selected von Frey hairs (between 6.2 and 140 g) were used 
for mechanical stimuli. The temperature of the cold stimulus was decreased in 
steps of 5 °C (between 20 and 5 °C) with a thermal rate of change of 2 °C/sec. 
The patients were informed that they could stop the stimulus sequence at any 
time. If a VAS score of 80 or more was reported for one of the intensities, no more 
stimuli were applied. In such a case, the same VAS score was assigned to all 
higher stimulus intensities in the series in order to allow analysis of the cumulative 
group data. This method allowed the construction of mean stimulus/response 
curves for pain intensity against graded mechanical and thermal stimuli.  
 
 2. 4. Statistical analysis  
SAS 8.2 software (SAS institute Inc, Cary, NC, USA) was used for data 
analysis. Quantitative variables were described with means and standard 
deviations (SD). Qualitative variables were described with proportions and 
percentages.  
2.4.1. Factor analysis using the principal component analysis as the 
method of extraction was carried out to confirm the factorial structure of the 
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NPSI, previously described in a smaller group of patients (Bouhassira et al 2004). 
The Catell scree test was used to determine the number of factors extracted. 
Independent factors were obtained by the Varimax rotation method.  
2.4.2. The Spearman correlation coefficient (Rho) was used to explore 
relationships between the symptoms of allodynia (to brush, pressure or cold) 
assessed using the NPSI (scored 0 to 10 on numerical scales) and quantitative 
measures of allodynia or hyperalgesia. Relationships were measured between: 
1) symptoms of pain evoked by brush and allodynia to brush (scored on a VAS); 
2) symptoms of pain evoked by pressure and mechanical pain thresholds or pain 
induced by mechanical suprathreshold stimuli (measured on the painful area or 
expressed as a difference between the painful and control sites and scored on a 
VAS); 3) symptoms of pain evoked by contact with cold and cold pain thresholds 
or pain induced by suprathreshold cold stimuli (measured on the painful area or 
expressed as a difference between the painful and control sites and scored on a 
VAS).  
2.4.3. Several multiple correspondence analyses (MCA) were used for 
simultaneous investigation of the relationships among neuropathic symptoms (or 
dimensions) and clinical characteristics of the patients (age, duration of pain, sex, 
localisation of pain, aetiology, type of the lesion, anatomical location of lesion).  
 
i- MCA with symptoms as dichotomous categories 
The ten neuropathic symptoms of the NPSI were classified into two 
dichotomous categories (0: absent;  1: present). Each category was considered 
a separate variable. The clinical characteristics of the patients were categorised 
in the following manner: by age, including seven categories of ten years each 
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(from 20-30 years to 80-90 years); by duration of pain (in months), without normal 
distribution, including four categories corresponding to the interquartile intervals 
(3 to 7.4 months, 7.4 to 33.1 months, 33.1 to 148.4 months, 148 to 480 months); 
by anatomical location of the lesion (central or peripheral); by pain localisation, 
including six categories (superior limb, inferior limb, 4 limbs, trunk, hemibody, 
face/neck); by lesion type, including seven categories (mononeuropathy, 
polyneuropathy, plexopathy, radiculopathy, amputation, spinal cord, brain); and 
by aetiology of the lesion, including ten categories (peripheral trauma, diabetic 
polyneuropathy, non-diabetic polyneuropathy, postherpetic neuralgia (PHN), 
idiopathic trigeminal neuralgia, stroke, spinal cord trauma, syringomyelia, spinal 
cord tumour, multiple sclerosis).  
In factor analysis (a similar method to MCA), the proportion of variance 
explained by each axis was calculated and the number of retained axes was 
chosen to obtain a total percentage of (acceptable) variance. The contribution of 
each category to each axis was calculated to determine the set of symptoms with 
maximal contribution to a given axis. The clinical characteristics of the patients 
and their symptoms were projected on several two dimensional spaces formed 
by the main axes (e.g. axes 1 and 2, axes 1 and 3, axes 2 and 3) in order to 
visualize their proximity (i.e. their association). This graphic representation 
(example in Fig. 2) aids visualisation of the associations between symptoms and 
clinical characteristics. Associations are detected only by the proximity of 
categories within the multidimensional space (which cannot be properly 
illustrated in a plane). Visually detected associations between symptoms and 
clinical characteristics were confirmed by using the coordinates of each variable 
on the retained axes to calculate the exact algebraic proximity (associations).  
    
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ii- MCA with dimensions of the NPSI as dichotomous categories  
The symptoms explored by the NPSI were categorised into five 
dimensions (eg, combination of symptoms, see methods), as confirmed in the 
present sample. Thus, we also used MCA (as described above) to examine 
possible associations (absent = 0 and present   1) between these five 
dimensions and the clinical characteristics of the patients.  
iii-  MCA with symptoms and dimensions as trichotomous categories  
Coding of variables may influence the results of multivariate analyses (14); 
thus, the two previous MCAs were carried out again as described above, with 
symptoms and dimensions coded according to their score on a 0 to 10 numerical 
scale: 1 (mild) = score of 0 to 2; 2 (moderate) = score of 3 to 7; 3 (severe) = 
score of 8 to 10.  
2.4.4 Confirmation of bivariate associations 
The chi square test was used to confirm associations between symptoms 
and clinical characteristics identified by MCA.   
For all tests, p values < 0.05 were considered significant.   
    
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3- RESULTS  
 This study included 482 consecutive patients. Demographic and clinical 
characteristics are indicated in Table 1. Mean pain intensity was 64 ± 19 and was 
similar across all the neuropathic entities. The proportion of patients reporting 
each neuropathic symptom is shown in Table 2.  
 3.1. Factor analysis of the NPSI 
 Factor analysis clearly confirmed the existence of a five-factor solution, 
which accounted for 78% of the total variance (Table 3). Factor 1 included the 
three items associated with evoked pain. Factor 2 included two items 
corresponding to paraesthesia/dysaesthesia. Factor 3 included two items 
associated with the deep component of spontaneous ongoing pain. Factor 4 
included two items related to paroxysmal pain. Factor 5 included one item 
(“burning”) corresponding to the superficial component of pain. This analysis, 
based on a large sample of patients, identified the same five factors as our 
previous study based on a smaller group. 
3.2. Relationships between self-reported evoked pain and 
allodynia/hyperalgesia assessed by quantitative sensory testing  
The 90 patients who underwent quantitative sensory tests were matched 
to the entire group for age (57 ± 14 years), sex (53% men, 46% women), duration 
of pain (77 ± 64 months) and aetiologies of pain (traumatic/post-surgical nerve 
lesion being the most common, followed by painful polyneuropathies, 
postherpetic neuralgia, syringomyelia, post-stroke pain, multiple sclerosis and 
spinal cord trauma). Most patients (93%) had clinically detectable mechanical 
and/or thermal deficits identified by a standard neurological examination.  
Most patients (68 patients, i.e. 76% of the sample) reported at least one 
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type of evoked pain on the NPSI (score   1/10) (Table 2). The symptoms of 
brush-evoked pain (scored from 0 to 10) significantly correlated with the 
magnitude of allodynia to brush (Fig 1A). Similarly, symptoms of pressure-evoked 
pain correlated with pain evoked by suprathreshold mechanical stimulation on the 
painful side (Fig 1B) and were inversely correlated, although to a lesser degree, 
with mechanical pain thresholds on the painful side (Rho: -0.67; p < 0.001). 
Symptoms of cold-evoked pain correlated with pain evoked by suprathreshold 
cold stimulation on the painful side (Fig 1C) and, although to a lesser extent, with 
cold-evoked pain thresholds (expressed as the difference betweeen the neutral 
temperature and absolute thresholds) on the painful side (Rho: 0.66, p < 0.0001).  
3-3 MCA: Multivariate associations between symptoms (as dichotomous 
categories) and clinical characteristics   
Four main axes were retained after MCA, accounting for 64.3% of the total 
variance. The proportion of total variance accounted for by each axis was 24.5% 
for axis 1, 15.8% for axis 2, 13.5% for axis 3 and 10.5% for axis 4.  
Fig 2 shows the projection of symptoms and clinical characteristics in the 
plane formed by axes 1 and 2. The absence of tingling and pins and needles was 
associated with PHN, trigeminal neuralgia and localisation to the face/neck. We 
observed no other association between painful symptoms and clinical 
characteristics.  
Fig 3 shows the projection of symptoms and clinical characteristics in the 
plane formed by axes 1 and 3. The absence of squeezing and pressure was 
associated with PHN. This was the only association we observed. 
Finally, the presence of the symptoms electric shocks and stabbing was 
associated with amputation pain and plexopathy (eg plexus avulsion) in the plane 
    
14 
formed by axes 1 and 4 (not shown). Calculation of exact algebraic proximity 
confirmed all the previously detected visual associations.  
3.4. MCA: Multivariate associations between dimensions of the NPSI (as 
dichotomous categories) and clinical characteristics  
We carried out the same analysis after replacing the symptoms with the 
dimensions of the NPSI. We observed associations between the absence of 
burning and the absence of paraesthesia and trigeminal neuralgia (Fig 4); 
between the presence of burning, the absence of deep pain and PHN; and 
between the presence of paroxysmal pain and amputation (Fig 4) and 
plexopathy.  
The absence of paraesthesia was also associated with PHN and 
trigeminal neuralgia, whereas the presence of evoked pain was associated with  
PHN in the plane formed by axes 1 and 2 (not shown). 
3.5. MCA: Multivariate associations between symptoms (and dimensions) 
as trichotomous variables and clinical characteristics  
We observed similar results when neuropathic symptoms (and 
dimensions) were categorised as trichotomous variables. Thus, mild tingling, pins 
and needles, squeezing and pressure pain were associated with PHN, trigeminal 
neuralgia and localisation to the face/neck and severe brush-evoked pain was 
associated with PHN (not shown).  
3.6 MCA: Multivariate associations between dimensions of the NPSI as 
trichotomous variables and clinical characteristics  
We also observed associations for mild paraesthesia, moderate and 
severe burning and PHN; and for mild burning, severe paroxysmal pain and 




3.7 Summary  
The only associations indicated by MCA were for PHN and moderate to 
severe burning pain, brush-evoked pain and the absence of deep pain and 
paraesthesia/dysaesthesia; trigeminal neuralgia and severe paroxysmal pain and 
the absence of the three dimensions burning pain, deep pain and 
paraesthesia/dysaesthesia; localisation to the face/neck (in which PHN and 
trigeminal neuralgia were highly predominant) and the absence of deep pain and 
paresthesia/dysesthesia  ; and plexus avulsion, amputation and paroxysmal pain.  
3.8. Results of univariate analyses 
The frequency of dimensions (determined from NPSI) for various 
aetiologies is indicated in Table 4. Univariate analyses confirmed all the 
associations between dimensions and aetiologies identified by MCA. Thus, the 
absence of burning was significantly associated with trigeminal neuralgia (chi 
square : 19.3; p < 0.0001). The absence of deep pain was associated with 
trigeminal neuralgia (chi square 8.7; p < 0.01) and PHN (chi square 16.8; p < 
0.0001). The presence of paroxysmal pain was associated with amputation pain 
(chi square: 5.2; p < 0.05), plexus avulsion (chi square: 5.5; p < 0.05) and 
trigeminal neuralgia (chi square : 4.2; p < 0.05). The presence of burning pain 
and allodynia was associated with PHN (chi square : 14.3 for burning pain; p < 
0.001; chi square : 14.8 for allodynia, p < 0.0001). The absence of 
paraesthesia/dysaesthesia was associated with trigeminal neuralgia (chi square 
21.7) and PHN (chi square 49.8) (p < 0.0001).  
Univariate analyses identified similar associations between the symptoms 
(squeezing, pressure, stabbing, electric shocks, tingling, pins and needles and 
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brush-evoked pain) and aetiologies. In particular, brush-evoked pain was 
observed in 93% of patients with PHN and in only 37 to 58% of the other patients 
(chi square 39.7; p < 0.0001).   
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4. DISCUSSION  
We investigated the relationships between positive symptoms, aetiologies 
and locations of neurological lesions in a large consecutive sample of patients 
with NP, representative of those seen in pain centres or neurology departments. 
We confirmed that NP symptoms that were self-reported on the NPSI pertain to 
distinct dimensions, corresponding to relevant clinical components (i.e. superficial 
pain, deep pain, paroxysmal pain, evoked pain, dysaesthesia/paraesthesia). 
However, NP clinical expression was "trans-aetiological", as MCA identified only 
a few associations between the presence (or absence) of various symptoms and 
specific aetiologies. Overall, our findings suggest that there are more similarities 
than differences in the neuropathic symptoms associated with a large variety of 
peripheral and central lesions.  
Assessment of NP symptoms in this study was based on the NPSI, which 
allows evaluation of core neuropathic symptoms, including burning pain, electric 
shocks, brush-evoked pain (8) and paraesthesia/dysaesthesia (i.e. tingling and 
pins and needles). We confirmed the internal structure of the questionnaire by 
factor analysis before it was used for multivariate analyses. Factor analysis 
indicated that neuropathic symptoms were categorised into five independent 
dimensions formed by specific combinations of symptoms that were identical to 
those reported in our previous study (8).  
We also verified the relevance of the assessment of symptoms of evoked 
pains with this questionnaire by showing clear correlations between self-reported 
evoked pain and allodynia/hyperalgesia assessed by the investigator using 
quantified sensory tests. These tests are the method of choice for quantification 
of allodynia and hyperalgesia (9). However, they are difficult to use in large 
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samples (18, 34, 39), despite their significant advantages for pathophysiological 
studies (3, 9, 13, 18). Additionally, normative values (30) are not relevant to 
elderly patients, are limited to some pain areas and do not include responses to 
suprathreshold stimulation, which may be less reliable on repeated examination 
(38). Our data demonstrate the validity of NPSI-based self-assessment of evoked 
pains, making it suitable for our study and for clinical practice and therapeutic 
trials.  
Multiple correspondence analyses are the most appropriate multivariate 
(multifactorial) methods to estimate associations between categorised variables 
(16, 17). These analyses indicated that idiopathic trigeminal neuralgia was 
strongly associated with electric shocks only. From a therapeutic perspective, 
only trigeminal neuralgia responds particularly well to sodium channel blockers, 
including carbamazepine, oxcarbazepine and lamotrigine (1, 25), which are more 
modestly effective for other neuropathic pain (1, 5, 36). Our data emphasize the 
relevance of distinct definitions, diagnostic and therapeutic algorithms for 
neuropathic pain and idiopathic trigeminal neuralgia (1, 35).  
Unexpectedly, PHN was different from other aetiologies on the basis of its 
symptom profile. PHN was characterised by a high prevalence (i.e. more than 
90% of the patients) of burning pain and allodynia (particularly brush-evoked 
pain) and the absence of deep pain and paraesthesia/dysaesthesia. Previous 
psychophysical studies have also reported brush-evoked allodynia in 78 to 100% 
of patients (24, 26, 31). From a therapeutic perspective, the response of PHN to 
the major drugs used for neuropathic pain — including gabapentin, pregabalin, 
tricyclics and opioids — does not seem specific (1, 14). However, this condition 
has particular symptomatic characteristics that may account, in part, for its 
    
19 
response to treatment. For instance, the NMDA antagonist dextromethorphan 
and the anti-epileptic lacosamide have no effect on this condition, whereas they 
have been found effective for other neuropathic pain syndromes (22, 29, 32). 
Conversely the topical agent capsaicin is effective for PHN, but has been 
reported to have minimal effect for painful polyneuropathies (1, 14). Our data 
challenge the relevance of using PHN as a model of neuropathic pain in 
pharmacological studies. Our findings also emphasize the need for large-scale 
studies to better investigate response profiles for PHN in comparison with those 
for other neuropathic conditions.  
Plexus avulsion and amputation pain were also different from other 
aetiologies in that they were closely associated with pain paroxysms (electric 
shocks, stabbing), which were present in 90% of patients with plexus avulsion 
and 100% of patients with amputation pain. These data are consistent with 
classic observations (23, 27) and may account for some of their therapeutic 
specificities, particularly the good efficacy of surgical procedures (e.g. dorsal root 
entry zone lesions) for pain paroxysms in plexus avulsion (33).  
Multiple correspondence analysis did not show associations between 
neuropathic symptoms (or dimensions) and the other aetiologies, types or 
locations of lesions or pain localisations (with the exception of the localisation 
“face/neck”, which shared common characteristics with PHN and trigeminal 
neuralgia, probably because both aetiologies were predominant in this pain 
area). In contrast, symptoms and dimensions were very similar for various 
aetiologies, without evidence for specific characteristics. Thus, symptoms alone 
are not discriminant enough to indicate specific aetiologies. Identifying 
neurological deficits and analysing their topography (both of which are directly 
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related to the nerve lesion itself) is essential for such a purpose (20, 28). The 
absence of associations between symptoms and almost all pain localisations 
suggests that lesion topography does not influence neuropathic characteristics of 
pain and should not determine the response to therapy. Symptoms were also not 
associated with duration of pain, sex or age. For example, symptoms were not 
more severe in patients with very long duration of pain than in those with pain for 
less than one year.  
Our data indicate that the clinical entity neuropathic pain has strong clinical 
consistency, although heterogeneous regarding aetiologies and types of nerve 
lesions. From a therapeutic perspective, our findings suggest that the current way 
of selecting patients on the basis of the disease or topography of the lesion might 
not be the most appropriate or rational approach (19). This is illustrated by 
pharmacological trials showing similar efficacy of most treatments of neuropathic 
pain due to various aetiologies, including painful polyneuropathies and central 
pain (1, 11, 14). The multidimensional nature of neuropathic symptoms supports 
the relevance of subgrouping patients on the basis of symptoms or dimensions in 
therapeutic trials. This categorisation, which has been used in only a few studies 
(9), should contribute to improved therapeutic response to treatments, compared 
to the current therapeutic approach (1, 14).  
In the present study, only positive neuropathic symptoms – either painful 
or non painful - but not negative ones (ie, sensory deficits), were considered for 
multivariate analyses. The latter are the hallmark of neuropathies and strongly 
related to the nature and severity of the nerve lesion, while they are not simply or 
directly correlated to the magnitude or characteristics of neuropathic pain (10, 12, 
15). However we cannot rule out the possibility that particular combinations of 
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positive and negative symptoms or signs would be associated with specific 
aetiologies or nerve lesions. Studies remain necessary to further investigate the 
relationships between positive symptoms, sensory deficits and aetiologies or 
nerve lesions.  
In conclusion, our findings indicate that there is a need for better 
assessment of positive symptoms and dimensions in large-scale pharmacological 
studies of neuropathic pain (19). This is a first step towards establishing a 
mechanism-based approach (3, 13, 37) for selecting therapy and should 
contribute to improvement  of  our current therapeutic strategies for these 
difficult-to-treat pains.  
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Table 1. Clinical and demographic characteristics of the patients included 
in the study (n = 482 patients) 
Clinical and demographic data 
 
Mean age ± SD (range) 
Sex: % men / % women (N) 
Mean duration of pain (months ± SD) (range) 
Mean pain intensity: VAS (range)  
57.7 ± 15.1 (20 - 90) 
53.5/46.4 (258/224) 
65 ± 80 (3 - 665) 
64 ± 19 (30 - 100) 
Site of injury/anatomical location of lesion 
 











 Amputation  
Central  
 
 Spinal cord 
 
 Brain 
72.4    (349) 
38.6   (186) 
8.9        (43) 
4.8        (23) 
18         (87) 
2.1        (10) 
27.6    (133) 
16.1   (78) 
11.4   (55) 
Aetiologies of neuropathic pain 
  
    %   (N) 
Peripheral trauma  
 
 Traumatic nerve lesion  
 
 Post-surgical nerve lesion2 
 
 Plexus avulsion3 
 
 Amputation pain with stump neuroma   
 
 Post-surgical radiculopathy4 
 
 Post-surgical trigeminal neuralgia5  
Diabetic painful polyneuropathy 




Central post-stroke pain7 
Spinal cord trauma 
Trigeminal neuralgia  
Spinal tumour8 
38.4 (185) 
8        (39) 
14.7   (71) 
4.8     (23) 
2.1     (10) 
8.9     (43) 
1.5       (7) 
7.3     (35) 
11      (53) 
10.2   (49) 
8.3 (40) 
6.5     (32) 
6.4 (31) 
5.1     (25) 
3.7     (18) 
1.2       (6) 
Topography of pain  
 







40      (193) 
29      (140) 
6.2      (30) 
10.4    (50) 
5.6      (27) 




1 Postherpetic neuralgia was classified as mononeuropathy. It generally involved 
the trunk (n = 27) or the face (n = 14), less commonly the upper or lower limb.  
2
 Post-surgical nerve lesion always concerned a major nerve: median, ulnar, 
radial, intercostobrachial or thoracic nerve of the upper limb; genitofemoral, 
femoral, sural or saphenous nerve of the lower limb.  
3 Plexus avulsion was the only cause of plexopathy. It was generally incomplete 
with partial deficit. 
4
 These patients had post-surgical lumbar radiculopathy in most cases (n = 40) 
and four had post-surgical cervicobrachial neuralgia. The diagnosis of 
radiculopathy was based on a documented history of root compression, typical 
clinical symptoms and signs (ie, pain radiating beyond the knee and evoked by 
straight leg raising in lumbar radiculopathy, motor/sensory or reflex deficits) and 
sometimes additional tests (eg EMG). 
5
 Symptomatic trigeminal neuralgia referred to post-thermocoagulation trigeminal 
neuralgia in all cases  
6 Non-diabetic polyneuropathy was predominantly idiopathic (n = 23) and more 
rarely due to immune disease (n = 12), drugs (n = 7), critical illness (n = 6), 
hereditary conditions (n = 3) or gammopathy (n = 2).  
7
 Central post-stroke pain was associated with ischemia (n = 18), hemorrhage 
(12) or lacunar infarction (1). It concerned the rolandic or parietal areas (n = 17), 
the thalamus (n = 8) or the brainstem (n = 6).  
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Table 2. Proportion of patients reporting symptoms (NPSI score   1/10) and 
mean intensity of symptoms (scored 0 to 10 on a numerical scale) in the 482 















Brush evoked pain 
Pressure evoked pain 
Cold evoked pain 
Tingling 











4.3 ± 3.6 
3.1 ± 3.6 
3.0 ± 3.5 
4.1 ± 3.9 
2.7 ± 3.6 
3.8 ± 3.8 
3.6 ± 3.8 
2.1 ± 3.4 
4.5 ± 3.7 




Table 3. Factor analysis with loadings for the ten items on the five-factor solution 
























Evoked by brushing 
Evoked by pressure 






















































Table 4. Frequency of dimensions of the NPSI (in %) for the most common aetiologies of neuropathic pain included in the study (n  
10 patients). Univariate analyses confirmed all the associations between dimensions and aetiologies identified by MCA (proportions 






















MS Syrinx  Stroke 
 N =49 N=35 N= 53 N =110 N=15 N=10 N=43 N=18 N=25 N=26 N=40 N=31 
Burning pain  
Deep pain 
Paroxysmal pain  































































Abbreviations : PHN : postherpetic neuralgia ; PPN : painful polyneuropathy ; MS : multiple sclerosis  






Correlations between symptoms of evoked pains (assessed using the NPSI) and 
signs of allodynia or hyperalgesia (evaluated using quantitative sensory testing 
on the painful side).  
A) Correlation between symptoms of brush-evoked pain (scored from 0 to 10 on 
a numerical scale) and allodynia to brush (scored from 0 to 100 on a VAS). Rho: 
0.83; p < 0.0001.  
B) Correlation between symptoms of pressure-evoked pain (scored from 0 to 10 
on a numerical scale) and pain induced by suprathreshold (140 g) von Frey hairs 
on the painful side (scored from 0 to 100 on a VAS). Rho: 0.79; p < 0.0001.  
C) Correlation between symptoms of cold-evoked pain (scored from  0 to 10 on a 
numerical scale) and pain induced by 5 °C stimulation on the painful side (scored 
from 0 to 100 on a VAS). Rho: 0.75; p < 0.0001. 
Similar relationships were found when the values obtained for pressure and cold 
were expressed as a difference between the painful and control sides (not 
shown). Significant relationships were also obtained when lower suprathreshold 






Multiple correspondence analysis (MCA) showing the associations between 
symptoms (blue squares), categorized as absent (0) or present (1) and clinical 
characteristics of the patients (red triangles), eg aetiologies, pain localisation, 
type of nerve lesion and location of the lesion in the plane formed by axes 1 and 
2 (see Methods for the categories of the clinical characteristics). All the 
categories are located in a Euclidian space. The closer the values, the more 
highly associated they are. For clarity of the presentation, age, sex and pain 
duration are not indicated.  
The bottom right quadrant of the figure shows that the categories postherpetic 
neuralgia, trigeminal neuralgia and localisation of pain to the face/neck are 
associated with absent tingling and pins and needles.  
Abbreviations : DPN: diabetic polyneuropathy; PPN: painful non-diabetic 




Figure 3  
 
Multiple correspondence analysis (MCA) showing the associations between 
symptoms (blue squares) categorized as absent (0) or present (1) and clinical 
characteristics of the patients (red triangles) in the plane formed by axes 1 and 
3 (see the legend of figure 2 for further details).  
The bottom right quadrant of the figure shows that the categories postherpetic 
neuralgia, trigeminal neuralgia and localisation of pain to the face/neck  are 
associated with absent squeezing and pressure.  
Abbreviations : DPN: diabetic polyneuropathy; PPN: painful non-diabetic 




Figure 4  
 
Multiple correspondence analysis (MCA) showing the associations between 
dimensions (eg, combination of symptoms) (blue squares) categorized as 
absent (0) or present (1) and clinical characteristics of the patients (red 
triangles) in the plane formed by axes 1 and 3 (see the legend of figure 2 for 
further details).  
The bottom of the figure shows that trigeminal neuralgia is associated with 
absent burning pain and paresthesia. The bottom left of the figure shows that 
amputation pain is associated with presence of paroxysmal pain.  Although not 
obvious in the bidimensional space, there was also an association between 
postherpetic neuralgia, presence of burning pain and absence of deep pain, 
and between plexopathy (eg plexus avulsion) and presence of paroxysmal pain.  
Abbreviations : DPN: diabetic polyneuropathy; PPN: painful non-diabetic 
polyneuropathy; PHN: postherpetic neuralgia; TN: trigeminal neuralgia.  
 
